Sequential homoharringtonine (HHT) and interferon (IFN-A) produce high hematologic and cytogenetic response rates in Philadelphia chromosome positive (Ph) chronic myelogenous leukemia (CML).

被引：0
|
作者：
O'Brien, S
Kantarjian, H
Koller, C
Andreeff, M
Feldman, E
Keating, M
Beran, M
Freireich, E
Rios, MB
Talpaz, M
机构：
来源：
BLOOD | 1998年 / 92卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2707
引用
收藏
页码：656A / 656A
页数：1
相关论文
共 50 条
  • [41] EFFICACY OF NILOTINIB IN PATIENTS (PTS) WITH NEWLY DIAGNOSED, PREVIOUSLY UNTREATED PHILADELPHIA CHROMOSOME (PH)-POSITIVE CHRONIC MYELOGENOUS LEUKEMIA IN EARLY CHRONIC PHASE (CML-CP)
    Cortes, J.
    Jones, D.
    O'Brien, S.
    Ferrajoli, A.
    Borhtakur, G.
    Burger, J.
    Wierda, W.
    Garcia-Manero, G.
    Letvak, L.
    Kantarjian, H.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 : 48 - 48
  • [42] Efficacy of Nilotinib in Patients (Pts) with Newly Diagnosed, Previously Untreated Philadelphia Chromosome (Ph)-Positive Chronic Myelogenous Leukemia in Early Chronic Phase (CML-CP)
    Cortes, Jorge
    O'Brien, Susan
    Jones, Dan
    Jabbour, Elias
    Konopleva, Marina
    Ferrajoli, Alessandra
    Kadia, Tapan
    Borthakur, Gautam
    Stigliano, Denise
    Shan, Jenny
    Kantarjian, Hagop
    BLOOD, 2009, 114 (22) : 144 - 145
  • [43] Clinical response and hematological toxicity to low dose alpha interferon (IFN) following hydroxyurea (HU) induced cytoreduction in a patient with variant Philadelphia chromosome positive (Ph Chr+) chronic myelocytic leukemia (CML).
    Hartung, B
    Besley, D
    Lopez, F
    Yee, S
    Mann, B
    BLOOD, 1997, 90 (10) : 3991 - 3991
  • [44] Prediction of initial cytogenetic response for subsequent major and complete cytogenetic response to imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia - Author reply
    Kantarjian, HM
    Cortes, J
    CANCER, 2003, 98 (08) : 1777 - 1778
  • [45] Frequency and Impact of Molecular Response's with Nilotinib (Tasigna) in Patients (Pts) with Newly Diagnosed Philadelphia Chromosome (Ph)-Positive Chronic Myelogenous Leukemia in Early Chronic Phase (CML-CP)
    Daver, Naval
    Kantarjian, Hagop M.
    O'Brien, Susan
    Jabbour, Elias
    Pierce, Sherry
    Lim, Miranda
    Borthakur, Gautam
    Pemmaraju, Naveen
    Konopleva, Marina
    DiNardo, Courtney D.
    Ravandi, Farhad
    Garcia-Manero, Guillermo
    Cortes, Jorge E.
    BLOOD, 2014, 124 (21)
  • [46] CORRELATION BETWEEN DENSITOMETRY QUANTITATION OF THE BREAKPOINT CLUSTER REGION REARRANGEMENT (BCR+) AND STANDARD CYTOGENETIC (CG) ANALYSIS IN PATIENTS WITH PHILADELPHIA-CHROMOSOME-POSITIVE (PH+) CHRONIC MYELOGENOUS LEUKEMIA (CML)
    VERSCHRAEGEN, C
    KANTARJIAN, H
    HIRSCHGINSBERG, C
    LEE, M
    CORK, A
    OBRIEN, S
    STASS, S
    RIOS, M
    TALPAZ, M
    BLOOD, 1993, 82 (10) : A42 - A42
  • [47] Results of triple therapy with interferon-alpha, cytarabine, and homoharringtonine, and the impact of adding imatinib to the treatment sequence in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in early chronic phase
    O'Brien, S
    Giles, F
    Talpaz, M
    Cortes, J
    Rios, MB
    Shan, JQ
    Thomas, D
    Andreeff, M
    Kornblau, S
    Fadedl, S
    Garcia-Manero, G
    White, K
    Mallard, S
    Freireich, E
    Kantarjian, HM
    CANCER, 2003, 98 (05) : 888 - 893
  • [48] Hommoharringtonine (HHT) and low-dose cytosine arabinoside (ARA-C) combination therapy has significant activity in patients (PTS) with late phase Philadelphia chromosome (Ph) - Positive chronic myelogenous leukemia (CML).
    Kantarjian, H
    OBrien, S
    Keating, M
    Beran, M
    Koller, C
    Estey, E
    Kornblau, S
    Rios, MB
    Talpaz, M
    BLOOD, 1996, 88 (10) : 2299 - 2299
  • [49] Treatment of Philadelphia chromosome positive chronic phase chronic myelogenous leukemia (Ph plus CML) with pegylated interferon alpha 2B (Peg-IFN/SCH54031) and low-dose cytosine arabinoside (ara-C)
    Manero, GG
    Talpaz, M
    Giles, F
    Cortes, J
    O'Brien, S
    Faderl, S
    Thomas, D
    Rios, MB
    Kantarjian, H
    BLOOD, 2001, 98 (11) : 258B - 258B
  • [50] Prognostic significance of additional cytogenetic abnormalities in newly diagnosed patients with Philadelphia chromosome-positive chronic myelogenous leukemia treated with interferon-α:: A Cancer and Leukemia Group B study
    Farag, SS
    Ruppert, AS
    Mrózek, K
    Carroll, AJ
    Pettenati, MJ
    Le Beau, MM
    Peterson, BL
    Powell, BL
    Ozer, H
    Silver, RT
    Larson, RA
    Bloomfield, CD
    INTERNATIONAL JOURNAL OF ONCOLOGY, 2004, 25 (01) : 143 - 151
12345